Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records.
OBJECTIVES: Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia. Our secondary objective was to assess and compare quit rates of smokers with versus without GP-recorded dementia who were prescribed varenicline or NRT for smoking cessation.
DESIGN: A retrospective cohort study based on the analysis of electronic medical records within the Clinical Practice Research Datalink (2007-2015).
SETTING: 683 general practices in England.
PARTICIPANTS: People with and without GP-recorded dementia, aged 18 years and have a code indicating that they are a current smoker.
INTERVENTION: Index prescription of varenicline or NRT (from 1 September 2006).
OUTCOME MEASURES: The primary outcomes were smoking prevalence and prescribing rates of varenicline and NRT (2007-2015). The secondary outcome was smoking cessation at 2 years.
RESULTS: Age and sex-standardised prevalence of smoking was slightly higher in people with GP-recorded dementia than in those without. There were 235 314 people aged 18 years and above prescribed NRT or varenicline. Among smokers with GP-recorded dementia (N=447), 409 were prescribed NRT and 38 varenicline. Smokers with GP-recorded dementia were 74% less likely (95% CI 64% to 82%) to be prescribed varenicline than NRT, compared with smokers without GP-recorded dementia. Compared with people without GP-recorded dementia, people with GP-recorded dementia had consistently lower prescribing rates of varenicline from 2007 to 2015. Two years after prescription, there was no clear evidence for a difference in the likelihood of smoking cessation after prescription of these medications between individuals with and without dementia (OR 1.0, 95% CI 0.8 to 1.2).
CONCLUSIONS: Between 2007 and 2015, people with GP-recorded dementia were less likely to be prescribed varenicline than those without dementia. Quit rates following prescription of either NRT or varenicline were similar in those with and without dementia.
|投稿者||Itani, Taha; Martin, Richard; Rai, Dheeraj; Jones, Tim; Taylor, Gemma; Thomas, Kyla; Munafo, Marcus; Davies, Neil; Taylor, Amy|
|組織名||Medical Research Council Integrative Epidemiology Unit, University of Bristol,;Bristol, UK email@example.com.;UK Centre for Tobacco and Alcohol Studies, School of Psychological Science,;University of Bristol, Bristol, UK.;Bristol, UK.;NIHR Biomedical Research Centre at the University Hospitals Bristol NHS;Foundation Trust and the University of Bristol, Bristol, UK.;Population Health Sciences, Bristol Medical School, University of Bristol,;Centre for Academic Mental Health, School of Social and Community Medicine,;Avon & Wiltshire Partnership NHS Mental Health Trust, Bristol, UK.;National Institute for Health Research Collaboration for Leadership in Applied;Health Research and Care West (NIHR CLAHRC West) at University Hospitals Bristol;NHS Foundation Trust, Bristol, UK.;Addiction and Mental Health Group (AIM) Department of Psychology, University of;Bath, Bath, UK.|